Perrigo Company plc (PRGO) Company Overview

What does Perrigo Company do?

Perrigo Company plc is a Dublin-domiciled, New York Stock Exchange-listed consumer health company trading under PRGO. Its core purpose is practical rather than glamorous: make self-care medicines and wellness products available across brands, store brands, categories, price points and geographies. The company’s official business-model description emphasizes affordable, reliable products that consumers can use to prevent or treat conditions they can manage without a physician. That places Perrigo between pharmaceutical manufacturing and consumer packaged goods.

Which products and customers define the company?

Perrigo sells pain and sleep aids, cough-cold and allergy products, digestive-health remedies, vitamins and healthy-lifestyle products, skin-care treatments, women’s health products, oral-care goods and infant formula. Its portfolio includes branded products such as Opill, ellaOne, Compeed, Solpadeine, Mederma, Jungle Formula and Physiomer, while a large part of the North American model is private-label manufacturing for retailers. The official product overview shows the breadth of this category coverage.

How does Perrigo make money?

Perrigo earns revenue when retailers, pharmacies, distributors and consumers buy finished self-care products. In store brands, Perrigo combines regulatory know-how, formulation, manufacturing scale and retailer relationships to produce products sold under a customer’s label. In branded care, the company captures more marketing economics but must also fund brand building, innovation and consumer demand generation. The central strategic tension is therefore clear: lower-margin scale businesses create cash and channel access, while higher-margin brands are expected to improve growth and profitability.

Which segment matters most?

The new product-category reporting structure introduced in Q1 2026 makes the model easier to read. Self Care generated $543 million of Q1 2026 sales, Specialty Care $207 million, Infant Formula $90 million and All Other $129 million. The company’s official segment recast explains that Self Care covers common self-treatment categories, Specialty Care includes women’s and skin health, and Infant Formula remains separate.

What drives margins and cash conversion?

Mix, plant utilization, retailer inventory, pricing, product launches and supply-chain efficiency drive gross profit. Branded women’s health and skin health can carry stronger margins, while infant formula and store-brand OTC are sensitive to factory volume. When volume falls, fixed manufacturing costs are spread over fewer units. That dynamic was visible in early 2026, when prior-year manufacturing volume headwinds reduced current-period earnings. Working capital also matters because inventory is substantial: Perrigo reported $1.149 billion of inventory at December 31, 2025, up from $1.082 billion a year earlier.

What did Perrigo’s latest quarter show?

The quarter ended March 28, 2026 was weak at the consolidated level but contained a meaningful split between pressured core categories and growing specialty products. The company’s Q1 2026 earnings release reported net sales of $969.2 million, down 7.2% from $1.044 billion in Q1 2025. Core sales were $842 million, down 8.3%, while core organic sales declined 11.0%.

Why did demand weaken?

Management attributed roughly 3.5 percentage points of the sales headwind to lower cough-and-cold incidence and another 3.0 points to lower retailer inventories. Core organic volume and mix declined 11.0%, while net pricing contributed only 0.2%. This is important because Perrigo’s business can be affected twice by a mild season: consumers buy less, then retailers reduce replenishment.

The reported loss was dominated by a non-cash goodwill impairment, not by the operating result alone. Even so, impairments are economically informative: they indicate that expected cash flows from acquired businesses have fallen below earlier assumptions. The Q1 2026 Form 10-Q recorded $77.4 million against Women’s Health, $66.3 million against Infant Formula and $187.2 million against Oral Care.

Which categories are strongest and weakest?

The category picture is mixed. Specialty Care is the clearest growth pocket: Q1 2026 sales rose 4.0% to $207 million, supported by Opill and ellaOne in women’s health. Its segment operating income increased 31.4% to $55 million. By contrast, Self Care sales fell 11.5% to $543 million and segment operating income dropped 39.3% to $68 million. Infant Formula sales increased 2.1% to $90 million, but the segment produced a $7 million operating loss versus $11 million of income a year earlier.

What does the annual category base reveal?

FY2025’s geographic reporting still shows the underlying product economics. Americas sales were $2.585 billion, with a 29.2% gross margin; International sales were $1.668 billion, with a 44.4% gross margin. In the Americas, upper respiratory generated $529.5 million, digestive health $442.1 million, nutrition $408.5 million, pain and sleep aids $332.5 million, healthy lifestyle $316.4 million, oral care $256.9 million and skin care $214.9 million. Internationally, skin care contributed $407.7 million, upper respiratory $288.2 million, pain and sleep aids $235.4 million, healthy lifestyle $231.5 million, vitamins and supplements $161.2 million, and women’s health $143.5 million.

What turning points shaped Perrigo’s strategy?

Perrigo’s current strategy is easier to understand as a sequence of moves from generic-drug roots toward global consumer self-care, followed by a period of portfolio repair. The relevant history is not corporate trivia; it explains why the company owns a wide set of brands, manufacturing assets, legal exposures and debt obligations.

1. 1887
   Founded in Michigan, establishing the manufacturing and retailer-service heritage that still supports private-label OTC products.
2. 2003
   The board adopted a regular quarterly dividend policy, creating a durable capital-allocation commitment.
3. 2013–2015
   The Elan and Omega transactions expanded Perrigo’s Irish structure, European brands and international complexity.
4. 2019
   The Ranir acquisition broadened oral self-care and deepened private-label category reach.
5. 2021–2022
   The company acquired HRA Pharma, adding women’s health and branded consumer products, including the platform that later launched Opill in the United States.
6. 2023
   Patrick Lockwood-Taylor became CEO, beginning a renewed focus on consumerization, execution and simplification.
7. 2024–2025
   Project Energize, supply-chain reinvention and portfolio divestitures sought to reduce complexity and restore dependable cash generation.
8. 2026
   Perrigo moved to product-category segments and completed the Dermacosmetics sale, sharpening visibility into Self Care, Specialty Care and Infant Formula.

How does the Three-S plan change the model?

At its 2025 investor day, Perrigo framed its plan as Stabilize, Streamline and Strengthen. Stabilize means improving store-brand OTC and infant-formula execution. Streamline means reducing portfolio and organizational complexity. Strengthen means putting more resources behind higher-growth brands. The official investor-day release described store brands and infant formula as cash generators for investment in “High-Grow” brands. The thesis depends on execution: savings must become better margins and cash flow rather than merely offsetting category weakness.

What gives Perrigo a competitive advantage?

Perrigo’s moat is not a single patent or consumer brand. It is a bundle of capabilities: regulated-product expertise, retailer relationships, broad formulation and manufacturing infrastructure, private-label scale, category breadth and the ability to serve many price points. Those assets make the company useful to large retailers that want reliable alternatives to national brands and to consumers seeking lower-cost self-care.

Where is the moat vulnerable?

Retailer power is high. Walmart represented 12.9% of FY2025 sales and the top ten customers represented 47%. Large customers can negotiate price, switch suppliers, reduce inventory or reallocate shelf space. Perrigo also competes with national-brand consumer-health companies, pharmaceutical manufacturers and other private-label producers. Its advantage is strongest where regulatory complexity, scale and retailer trust matter; it is weaker where products are easily copied, brands lack consumer pull or factories run below efficient utilization.

How financially strong is Perrigo?

Perrigo has meaningful scale and positive adjusted earnings, but leverage and uneven cash conversion limit flexibility. FY2025 net sales were $4.253 billion and gross profit was $1.495 billion, producing a 35.1% reported gross margin. Research and development expense was $95.4 million, selling expense $526.5 million and administration expense $435.9 million. Large goodwill impairments pushed reported operating results deeply negative, highlighting the gap between adjusted performance and the economics of past acquisitions.

How much balance-sheet pressure exists?

At March 31, 2026, cash and cash equivalents were $357 million and total debt was $3.6 billion. The company had $970 million outstanding under Term Loan B and $427.6 million drawn on its revolver at March 28, 2026. Credit ratings were below investment grade, including Ba3 from Moody’s, B+ from S&P and BB from Fitch, with negative outlooks from Moody’s and Fitch and a stable outlook from S&P as disclosed in the quarterly filing. This raises the importance of divestiture proceeds, free cash flow and debt reduction.

How does capital allocation affect the story?

Perrigo paid $159.3 million of dividends in FY2025, or $1.16 per share, compared with $152.5 million and $1.10 per share in FY2024. In February 2026, the board again declared a $0.29 quarterly dividend. The dividend supports an income-oriented investor base, but it also competes with debt reduction and reinvestment. The Dermacosmetics disposal, completed after Q1 2026, brought €305.6 million of upfront cash plus up to €27 million contingent on sales milestones, giving management a concrete source of deleveraging capital.

Who owns Perrigo stock, and how is it governed?

Perrigo has a conventional public-company ownership structure rather than founder control or a dual-class voting system. Ordinary shares generally carry one vote each, so economic ownership and voting influence are aligned. That makes large institutions, proxy advisers and the board’s capital-allocation credibility important. The latest 2026 proxy statement is the principal official source for beneficial ownership, board structure and executive-pay design.

What should investors infer from the ownership profile?

Dispersed ownership can strengthen accountability because management cannot rely on a controlling shareholder. It can also increase pressure for measurable progress on margins, cash conversion and leverage. For Perrigo, executive incentives should be assessed against outcomes that matter economically: organic sales, adjusted operating income, cash generation, debt reduction and total shareholder return. Board refreshment in 2026 reinforces the expectation that directors will oversee portfolio choices and execution rather than preserve legacy complexity.

What are Perrigo’s biggest opportunities?

The opportunity set is less about entering unfamiliar industries and more about improving the quality of an existing global self-care platform. First, Specialty Care can continue to expand through women’s health products such as Opill and ellaOne and through skin-health franchises. Second, store-brand share gains can offset weak category consumption when retailers seek value alternatives. Third, supply-chain and organizational savings can raise margins if manufacturing volumes stabilize.

Could simplification unlock value?

Yes, but only if disposals reduce debt and management complexity without removing too much earnings power. The Dermacosmetics sale is a concrete example: it generated cash, narrowed the portfolio and may improve strategic focus. The deeper opportunity is to create a cleaner operating model in which fewer brands and plants receive better investment, forecasting and supply-chain support. That can improve service levels, reduce working capital and make segment accountability more transparent.

What risks could weaken Perrigo’s outlook?

The most immediate risk is that weak consumption and retailer destocking persist longer than expected. Because Perrigo has meaningful fixed manufacturing costs, lower volumes can hurt margins faster than sales alone suggest. Customer concentration compounds this exposure: Walmart represented 12.9% of FY2025 sales, and the top ten customers represented 47%.

Which filing risks matter most?

The 2025 Form 10-K highlights competition, innovation execution, regulation, product recalls, supply-chain disruption, customer concentration, pricing pressure, litigation and leverage. These risks are linked rather than independent. For example, a quality problem can cause a recall, reduce retailer confidence, lower production volumes, compress margins and make deleveraging harder.

Legal exposure also remains relevant. At March 28, 2026, Perrigo recorded a $43 million accrual related to price-fixing lawsuits and a recovery receivable for half that amount. Geopolitical and tariff risks can also affect sourcing and margins. Q1 2026 included a roughly $21 million recovery of previously paid tariffs, showing that trade policy can create both expense and timing volatility.

Which KPIs matter most for valuation?

A Perrigo valuation should not begin with reported net income because impairment charges can obscure recurring operations. A better framework starts with core organic sales, gross margin, adjusted operating margin, cash conversion, net leverage and the mix between Self Care and Specialty Care. The company reaffirmed FY2026 adjusted EPS of $2.00–$2.30 all-in and $2.25–$2.55 for core ex-divestitures, while expecting approximately $156 million of net interest expense and an adjusted tax rate near 20%.

How should a researcher model Perrigo?

A reasonable model separates volume recovery from margin recovery. Revenue scenarios should distinguish seasonal OTC categories, Specialty Care, Infant Formula and portfolio exits. Gross margin should reflect plant utilization, mix and savings rather than simply extrapolating one quarter. Operating expenses should include reinvestment needed to support brands. Free cash flow equals operating cash flow minus capital expenditure, but working-capital swings require normalization. Finally, enterprise value must be reconciled with debt, lease obligations, divestiture proceeds and any contingent consideration.

What is the key takeaway from Perrigo analysis?

Perrigo matters because it is one of the few scaled businesses connecting regulated consumer-health manufacturing, retailer private labels and branded self-care across North America and Europe. Its breadth creates real barriers to entry and broad shelf access, but that same breadth has produced complexity, underperforming acquisitions and a leveraged balance sheet.